{"contentid": 488723, "importid": NaN, "name": "Full program for AstraZeneca at ASCO 2021", "introduction": "While UK-based drugmaker AstraZeneca has mostly made headlines of late for its development of a coronavirus vaccine, the firm\u00e2\u0080\u0099s work in oncology is potentially of greater significance.", "content": "<p>While UK-based drugmaker AstraZeneca (LSE: AZN) has mostly made headlines of late for its development of a coronavirus vaccine, the firm&rsquo;s work in oncology is potentially of greater significance.</p>\n<p>At the annual meeting of the American Society of Clinical Oncology (ASCO), kicking off on June 4, the firm is presenting data from more than 100 abstracts, including four abstracts selected as late-breakers, 12 oral presentations and one plenary presentation.</p>\n<p>Among the most important results, executive vice president for oncology Dave Fredrickson pointed to efforts to &ldquo;strengthen our leading portfolio in lung and breast cancers as well as hematology.&rdquo;</p>\n<p>Also of significance is new data for Lynparza (olaparib) and Imfinzi (durvalumab), as well as for Calquence (acalabrutinib).</p>\n<h2>Presentation highlights</h2>\n<p>A plenary presentation of results from the OlympiA Phase III trial in early breast cancer will highlight the impact of Lynparza (olaparib) on the risk of disease recurrence versus placebo in the adjuvant treatment of certain people with early breast cancer.</p>\n<p>Together with Merck &amp; Co (NYSE: MRK), AstraZeneca has led the way with Lynparza, a new form of treatment which continues to break ground in different treatment settings.</p>\n<p>In February 2021, the trial&rsquo;s Independent Data Monitoring Committee recommended moving to early primary analysis based on a planned interim analysis showing a sustainable and clinically relevant treatment effect in the primary endpoint of invasive disease-free survival.</p>\n<h2>Oral presentations</h2>\n<p>AstraZeneca will present first results of a head-to-head trial of Calquence versus ibrutinib, marketed as Imbruvica, in previously treated chronic lymphocytic leukemia (CLL).</p>\n<p>An oral presentation from the ELEVATE-RR Phase III trial will demonstrate significantly lower atrial fibrillation, fewer cardiac events and fewer discontinuations with Calquence, confirming a favorable benefit-risk profile.</p>\n<p>In addition, updated data from DESTINY-Gastric01 and DESTINY-CRC01 point to the potential of the antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) across HER2-targetable cancers, as well as in hard-to-treat patient populations.</p>\n<p>Finally, an oral presentation will outline results from EFFORT, a Phase II study of adavosertib with or without Lynparza in women with PARP-resistant ovarian cancer.</p>", "date": "2021-05-25 10:19:00", "meta_title": NaN, "meta_keywords": "AstraZeneca, oncology, presentation, significance, data, ASCO, treatment, results, Lynparza, oral, program, Full, work, coronavirus, UK-based, drugmaker", "meta_description": "While UK-based drugmaker AstraZeneca has mostly made headlines for its development of a coronavirus vaccine, the firm\u00e2\u0080\u0099s work in oncology is potentially of great", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-25 09:15:19", "updated": "2021-05-25 10:19:33", "access": NaN, "url": "https://www.thepharmaletter.com/article/full-program-for-astrazeneca-at-asco-2021", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "astrazeneca_big.jpg", "image2id": "astrazeneca_small-1.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Oncology", "topic_tag": "ASCO, Conferences, Drug Trial, Research", "geography_tag": "UK, USA", "company_tag": "AstraZeneca", "drug_tag": "Calquence, Enhertu, Lynparza", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-25 10:19:00"}